Pulmonary/Respiratory Diseases | Phase I Developments

Renovion

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

Lead Product(s): ARINA-1

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: ARINA-1

Highest Development Status: Phase I Product Type: Undisclosed

Partner/Sponsor/Collaborator: White Rock Capital Management

Deal Size: $8.1 million Upfront Cash: Undisclosed

Deal Type: Series A Financing June 18, 2020

Details:

Funds to be used for the development and clinical programs associated with Renovion's lead therapeutic candidate ARINA-1. ARINA-1 is a nebulized therapy developed to improve mucus clearance and decrease inflammation in patients diagnosed with chronic lung disease.

Imperial College London

Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

Lead Product(s): TRV027

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Trevena

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration June 02, 2020

Details:

Collaboration to evaluate the potential of TRV027, a novel AT1 receptor selective agonist, to treat acute lung injury contributing to acute respiratory distress syndrome (ARDS) in COVID-19 patients.

Aqualung Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Aqualung Therapeutics Gets $2.3 M NIH Fast-Track Award To Develop Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury

Lead Product(s): ALT-100

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: National Institute of Health

Deal Size: $2.3 million Upfront Cash: Undisclosed

Deal Type: Funding June 02, 2020

Details:

The funding is based on the company's progress in completion of the initial Fastrack Phase I studies of its novel immune-based anti-inflammatory therapeutic antibody for critically ill patients with acute lung injury.

Cellenkos

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Cellenkos Gets FDA Clearance to Initiate Phase 1 Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells for COVID-19 Associated ARDS

Lead Product(s): Cord Blood-Derived T-Regulatory Cells

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 02, 2020

Details:

US Food & Drug Administration (FDA) has cleared the way to initiate a Phase 1 clinical trial of CK0802 (Cryopreserved Cord Blood Derived T-Regulatory Cells) for treatment of COVID-19 associated acute respiratory distress syndrome (ARDS).

NantKwest

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients

Lead Product(s): BM-Allo.MSC

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 18, 2020

Details:

Preliminary data from NantKwest collaborators suggests mesenchymal stem cell treatments may benefit COVID-19 patients with acute respiratory distress syndrome and cytokine storm.

Genkyotex

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

FRANCE France

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Genkyotex Receives Approval From the French Medicines Agency (ANSM) to Initiate a Phase 1 Clinical Study With High-dose Setanaxib

Lead Product(s): Setanaxib

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 13, 2020

Details:

This Phase 1 study will evaluate setanaxib at doses up to 1600 mg/day in up to 54 subjects. Genkyotex is currently discussing the registration strategy for setanaxib in PBC with FDA and EMA.

Roivant Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19

Lead Product(s): Gimsilumab

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 27, 2020

Details:

Roivant Sciences and Altasciences are workig together for the development of gimsilumab as a potential treatment for SARS CoV-2 related acute respiratory distress syndrome.

TFF Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder

Lead Product(s): Voriconazole

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 19, 2020

Details:

Successfully completes single ascending dose phase of first clinical study in healthy subjects for a direct-to-lung, Thin Film Freezing (TFF) dry-powder formulation.

BioDelivery Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting

Lead Product(s): Buprenorphine

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 27, 2020

Details:

BELBUCA effect on respiratory drive was comparable to placebo at all doses tested.The effect of immediate release oral oxycodone HCl resulted in a dose-dependent decrease in respiratory drive.

Algernon Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

CANADA Canada

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment

Lead Product(s): Ifenprodil Tartrate

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 17, 2020

Details:

Algernon Pharma has appointed Novotech as the contract research organization for the its upcoming Phase 2 idiopathic pulmonary fibrosis and chronic cough study for the drug candidate NP-120.

Find

Find Drugs for Pulmonary/Respiratory Diseases in Phase I Clinical Development

Phase I

Product Type

Companies

Renovion

Renovion Announces Completion of $8.1 Million Financing Round Enabling Clinical Programs in Chronic Inflammatory Lung Diseases

Imperial College London

Trevena Announces Collaboration with Imperial College London to Evaluate TRV027 in COVID-19 Patients

Aqualung Therapeutics

Aqualung Therapeutics Gets $2.3 M NIH Fast-Track Award To Develop Novel Therapeutic Antibody For Patients With Radiation-Induced Lung Injury

Cellenkos

Cellenkos Gets FDA Clearance to Initiate Phase 1 Trial of Cryopreserved Cord Blood-Derived T-Regulatory Cells for COVID-19 Associated ARDS

NantKwest

NantKwest Announces FDA Authorization of IND Application for Mesenchymal Stem Cell Product for the Treatment of Severe COVID-19 Patients

Genkyotex

Genkyotex Receives Approval From the French Medicines Agency (ANSM) to Initiate a Phase 1 Clinical Study With High-dose Setanaxib

Roivant Sciences

Altasciences Completes Phase I Study on Gimsilumab for ARDS in COVID-19

TFF Pharmaceuticals

TFF Pharmaceuticals Announces Phase 1 Clinical Trial Progress for Voriconazole Inhalation Powder

BioDelivery Sciences

BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting

Algernon Pharmaceuticals

Algernon Pharmaceuticals Appoints Novotech as CRO for First Phase 2 Trial and Announces Novotech’s $220K Equity Investment